Named Bioactive Compounds · Compound
Amygdalin
Moderate Evidencecompound2 PubMed Studies
Hermetica Superfood Encyclopedia
Amygdalin is a cyanogenic glycoside found primarily in bitter apricot kernels and apple seeds that releases hydrogen cyanide upon enzymatic hydrolysis by beta-glucosidase in the gut. Despite being marketed as 'Laetrile' or 'Vitamin B17' for cancer treatment, clinical evidence does not support its efficacy and its cyanide-releasing mechanism poses serious toxicity risks.
Amygdalin is a cyanogenic glycoside naturally occurring in the kernels of stone fruits, particularly apricots, peaches, and almonds. It is extracted from plant tissues through standard isolation methods and belongs to a class of plant defense compounds. Chemically, it is a nitrile-containing glucoside that metabolizes to release cyanide when enzymatically hydrolyzed by beta-glucosidase.
Two FDA-approved, NCI-sponsored clinical trials in the late 1970s-early 1980s tested amygdalin in cancer patients. The Phase I study (6 patients) established dosing parameters, while the Phase II study (175 patients) found no substantive benefit for cancer treatment, with only one patient meeting response criteria. An additional trial of 178 patients similarly found no benefit for cancer cure, improvement, stabilization, symptom relief, or life extension.
Clinically studied doses include: Intravenous administration at 4.5 g/m² body surface area per day for 21 days; oral maintenance therapy following IV treatment (specific doses varied). Current practitioners use IV infusions ranging from 3-27 g based on perceived response, though no standardized, evidence-based dosing regimen exists. Consult a healthcare provider before starting any new supplement.
Amygdalin is a cyanogenic glycoside compound (C20H27NO11), not a food ingredient with a conventional nutritional profile. Molecular weight: 457.43 g/mol. It is not a source of macronutrients (proteins, fats, carbohydrates in nutritional sense) or conventional micronutrients. Bioactive composition: Amygdalin itself constitutes the primary compound of interest; upon hydrolysis by intestinal beta-glucosidases or endogenous enzymes, it yields hydrogen cyanide (HCN) at approximately 58-60 mg HCN per gram of amygdalin, benzaldehyde (~30% by molecular weight), and glucose (~35% by molecular weight). Found naturally in bitter almonds at approximately 1-3% dry weight, apricot kernels at 0.5-3.5% dry weight, apple seeds at 1-4 mg/g, and peach kernels at approximately 2-3% dry weight. Bioavailability notes: Oral bioavailability is significantly higher than intravenous due to gut microbial and mucosal beta-glucosidase activity accelerating HCN release; estimated lethal oral dose of HCN is 0.5-3.5 mg/kg body weight, making oral amygdalin substantially more toxic than parenteral forms. No fiber, protein, vitamin, or mineral content attributable to amygdalin as an isolated compound. Commercially sold as 'Laetrile' (a semi-synthetic derivative, amygdalin hydrolase product) at doses of 500-1000 mg tablets or 3-9 g intravenous preparations in historical trials.
Amygdalin is hydrolyzed by intestinal beta-glucosidase enzymes into glucose, benzaldehyde, and hydrogen cyanide (HCN), which inhibits cytochrome c oxidase in the mitochondrial electron transport chain, disrupting cellular respiration. Proponents hypothesized that elevated beta-glucosidase activity in tumor cells would produce localized cytotoxic HCN concentrations, while rhodanese enzyme in healthy tissue would detoxify it by converting cyanide to thiocyanate. This selective toxicity hypothesis has not been validated in vivo, and systemic cyanide release occurs non-selectively, creating toxicity in healthy tissues.
A landmark Phase II clinical trial conducted by the Mayo Clinic and three other cancer centers enrolled 175 cancer patients treated with amygdalin (Laetrile) combined with a metabolic therapy regimen. Only 1 patient met objective response criteria, representing a 0.6% response rate, with no complete or partial remissions observed in the broader cohort. Approximately 20% of patients reported temporary symptomatic relief, though this did not correlate with measurable tumor regression or improved survival. The National Cancer Institute concluded there is strong clinical evidence against amygdalin's efficacy as a cancer treatment, and it remains unapproved by the FDA.
Amygdalin poses a serious risk of acute cyanide poisoning, with symptoms including headache, dizziness, nausea, vomiting, hypotension, and potentially fatal respiratory failure at higher exposures. Oral ingestion is more dangerous than intravenous administration because gut bacteria and beta-glucosidase enzymes dramatically increase cyanide release; concurrent consumption of raw almonds, cruciferous vegetables, or other beta-glucosidase-rich foods amplifies this risk. Amygdalin is absolutely contraindicated in pregnancy due to cyanide's teratogenic and fetotoxic potential, and it should not be combined with high-dose vitamin C supplementation, which has been shown to enhance cyanide absorption in clinical case reports. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency face heightened toxicity risk, and no safe therapeutic dosage window has been established.
